Ulisse Biomed S.p.A. (BIT:UBM)
Italy · Delayed Price · Currency is EUR 1.015
+0.015 (1.50%)
Nov 3, 2025, 9:23 AM CET
Ulisse Biomed Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 0.93 | 0.77 | 0.07 | 0.14 | 0.28 | 0.5 | Upgrade |
Other Revenue | - | - | - | - | 0 | 0.11 | Upgrade |
| 0.93 | 0.77 | 0.07 | 0.14 | 0.28 | 0.61 | Upgrade | |
Revenue Growth (YoY) | 119.96% | 1059.87% | -52.18% | -50.64% | -53.68% | 5469.84% | Upgrade |
Cost of Revenue | 1.73 | 1.84 | 1.62 | 1.03 | 0.55 | 0.3 | Upgrade |
Gross Profit | -0.8 | -1.08 | -1.55 | -0.89 | -0.27 | 0.31 | Upgrade |
Selling, General & Admin | 1.67 | 2.07 | 0.61 | 0.43 | 0.2 | 0.18 | Upgrade |
Amortization of Goodwill & Intangibles | 2.85 | 2.74 | 2.61 | 0.28 | 0.21 | 0.01 | Upgrade |
Other Operating Expenses | -0.02 | 0.12 | 0.04 | -0.23 | -0.11 | -0.15 | Upgrade |
Operating Expenses | 4.69 | 5.12 | 3.3 | 0.52 | 0.34 | 0.08 | Upgrade |
Operating Income | -5.49 | -6.19 | -4.85 | -1.41 | -0.6 | 0.22 | Upgrade |
Interest Expense | -0.02 | -0.02 | -0 | -0 | -0 | -0 | Upgrade |
Interest & Investment Income | - | - | - | 0 | - | 0 | Upgrade |
Currency Exchange Gain (Loss) | -0 | -0 | -0 | -0 | -0 | -0 | Upgrade |
Other Non Operating Income (Expenses) | 0.21 | 0.28 | 0.05 | 0.11 | 0 | 0 | Upgrade |
EBT Excluding Unusual Items | -5.3 | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade |
Pretax Income | -5.3 | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade |
Income Tax Expense | - | - | - | - | - | 0 | Upgrade |
Net Income | -5.3 | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade |
Net Income to Common | -5.3 | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade |
Shares Outstanding (Basic) | 24 | 24 | 22 | 8 | 8 | - | Upgrade |
Shares Outstanding (Diluted) | 24 | 24 | 22 | 8 | 8 | - | Upgrade |
Shares Change (YoY) | 12.28% | 13.50% | 167.46% | 0.01% | - | - | Upgrade |
EPS (Basic) | -0.22 | -0.24 | -0.22 | -0.16 | -0.07 | - | Upgrade |
EPS (Diluted) | -0.22 | -0.24 | -0.22 | -0.16 | -0.07 | - | Upgrade |
Free Cash Flow | -2.66 | -3.56 | -0.97 | -1.05 | -0.39 | -0.6 | Upgrade |
Free Cash Flow Per Share | -0.11 | -0.14 | -0.04 | -0.13 | -0.05 | - | Upgrade |
Gross Margin | -86.89% | -140.15% | - | - | -94.64% | 50.57% | Upgrade |
Operating Margin | -593.23% | -806.30% | -7322.92% | -1020.66% | -215.17% | 37.03% | Upgrade |
Profit Margin | -572.63% | -773.49% | -7245.12% | -944.65% | -215.23% | 36.64% | Upgrade |
Free Cash Flow Margin | -287.64% | -463.78% | -1470.94% | -757.58% | -140.77% | -99.52% | Upgrade |
EBITDA | -1.77 | -3.27 | -2.35 | -1.29 | -0.36 | 0.28 | Upgrade |
EBITDA Margin | -191.50% | - | - | - | -126.84% | 45.43% | Upgrade |
D&A For EBITDA | 3.72 | 2.92 | 2.5 | 0.12 | 0.25 | 0.05 | Upgrade |
EBIT | -5.49 | -6.19 | -4.85 | -1.41 | -0.6 | 0.22 | Upgrade |
EBIT Margin | - | - | - | - | -215.17% | 37.03% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 1.04% | Upgrade |
Revenue as Reported | 1.23 | 1.24 | 0.26 | 0.52 | 0.41 | 0.76 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.